NEOTHYLLINE Drug Patent Profile
When do Neothylline patents expire, and when can generic versions of Neothylline launch?
Neothylline is a drug marketed by Teva and is included in two NDAs.
The generic ingredient in NEOTHYLLINE is dyphylline. There is one drug master file entry for this compound. Additional details are available on the dyphylline profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NEOTHYLLINE?
- What are the global sales for NEOTHYLLINE?
- What is Average Wholesale Price for NEOTHYLLINE?
Summary for NEOTHYLLINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 91 |
| Patent Applications: | 3,892 |
| DailyMed Link: | NEOTHYLLINE at DailyMed |
US Patents and Regulatory Information for NEOTHYLLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | NEOTHYLLINE | dyphylline | ELIXIR;ORAL | 007794-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva | NEOTHYLLINE | dyphylline | TABLET;ORAL | 007794-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva | NEOTHYLLINE | dyphylline | INJECTABLE;INJECTION | 009088-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva | NEOTHYLLINE | dyphylline | TABLET;ORAL | 007794-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
